Haematopoietic stem cell reprogramming and the hope for a universal blood product

• Published in: FEBS letters 2019-12, Vol.593 (23), p.3253-3265
• Main Authors: Barcia Durán, José Gabriel, Lis, Raphaël, Rafii, Shahin
• Format: Article
• Language: English
• Subjects: haematopoietic stem cells; pluripotent cell reprogramming; somatic cell reprogramming
• ISSN: 0014-5793; 1873-3468
• DOI: 10.1002/1873-3468.13681

Haematopoietic stem cells (HSCs) are the only adult stem cells with a demonstrated clinical use, even though a tractable method to maintain and expand human HSCs in vitro has not yet been found. Owing to the introduction of transplantation strategies for the treatment of haematological malignancies and, more recently, the promise of gene therapy, the need to improve the generation, manipulation and scalability of autologous or allogeneic HSCs has risen steeply over the past decade. In that context, reprogramming strategies based on the expression of exogenous transcription factors have emerged as a means to produce functional HSCs in vitro. These approaches largely stem from the assumption that key master transcription factors direct the expression of downstream target genes thereby triggering haematopoiesis. Both somatic and pluripotent cells have been used to this end, yielding variable results in terms of haematopoietic phenotype and functionality. Here, we present an overview of the haematopoietic reprogramming methods reported to date, provide the appropriate historical context and offer some critical insight about where the field stands at present.